DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG)
Publication
, Conference
Desjardins, A; Randazzo, D; Chandramohan, V; Peters, K; Johnson, M; Thomas, L; Threatt, S; Bullock, C; Herndon, J; Boulton, S; Healy, P ...
Published in: NEURO-ONCOLOGY
November 5, 2018
ATIM-16
Duke Scholars
Published In
NEURO-ONCOLOGY
DOI
EISSN
1523-5866
ISSN
1522-8517
Publication Date
November 5, 2018
Volume
20
Issue
suppl. 6; abstr ATIM-36
Start / End Page
vi9 / vi9
Location
New Orleans, LA
Publisher
OXFORD UNIV PRESS INC
Conference Name
23rd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd CNS Anticancer Drug Discovery and Development Conference
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Desjardins, A., Randazzo, D., Chandramohan, V., Peters, K., Johnson, M., Thomas, L., … Bigner, D. (2018). DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). In NEURO-ONCOLOGY (Vol. 20, pp. vi9–vi9). New Orleans, LA: OXFORD UNIV PRESS INC. https://doi.org/10.1093/neuonc/noy148.031
Desjardins, Annick, Dina Randazzo, Vidya Chandramohan, Katherine Peters, Margaret Johnson, Leslie Thomas, Stevie Threatt, et al. “DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG).” In NEURO-ONCOLOGY, 20:vi9–vi9. OXFORD UNIV PRESS INC, 2018. https://doi.org/10.1093/neuonc/noy148.031.
Desjardins A, Randazzo D, Chandramohan V, Peters K, Johnson M, Thomas L, et al. DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2018. p. vi9–vi9.
Desjardins, Annick, et al. “DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG).” NEURO-ONCOLOGY, vol. 20, no. suppl. 6; abstr ATIM-36, OXFORD UNIV PRESS INC, 2018, pp. vi9–vi9. Manual, doi:10.1093/neuonc/noy148.031.
Desjardins A, Randazzo D, Chandramohan V, Peters K, Johnson M, Thomas L, Threatt S, Bullock C, Herndon J, Boulton S, Healy P, Lipp E, Sampson J, Friedman A, Friedman H, Ashley D, Bigner D. DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2018. p. vi9–vi9.
Published In
NEURO-ONCOLOGY
DOI
EISSN
1523-5866
ISSN
1522-8517
Publication Date
November 5, 2018
Volume
20
Issue
suppl. 6; abstr ATIM-36
Start / End Page
vi9 / vi9
Location
New Orleans, LA
Publisher
OXFORD UNIV PRESS INC
Conference Name
23rd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd CNS Anticancer Drug Discovery and Development Conference
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences